Articles tagged with Prostate Cancer
Researchers in Guangdong, China have developed a new non-invasive method to screen for prostate cancer using surface-enhanced Raman scattering (SERS) spectroscopy combined with support vector machine (SVM) analysis. The technique achieved an accuracy of 98.1 percent in identifying cases of cancer.
A study of 1,806 men with prostate cancer found that those consuming high amounts of tomatoes and lycopene had an 18% lower risk of developing the disease. Men are advised to eat a wide variety of fruits and vegetables, maintain a healthy weight, and stay active to reduce their risk.
A UCLA study found that men with low prostate cancer knowledge experience increased decisional conflict and lower perceived effectiveness of treatment. Doctors can help by providing educational information before consultations to increase patients' comprehension and reduce regret.
A new study found that robot-assisted radical prostatectomy (RARP) procedures for prostate cancer increased from 0.7% to 42% among US surgeons between 2003 and 2010. RARP adoption was associated with higher volume providers and decreased costs over time.
Researchers matched 25 patients' treatment outcomes with their tumor's RNA sequence, finding similarities that could aid diagnosis and predict effective treatment. The study suggests that RNA sequencing may be a useful tool to aid personalized medicine in prostate cancer.
A nationwide population-based study in Sweden found that six percent of men filled a prescription for antibiotics within 30 days after having a prostate biopsy, with a twofold increase in hospital admissions over five years. Men with prior infections or significant comorbidities were at highest risk.
A European trial with 13-year follow-up found that prostate-specific antigen (PSA) testing can reduce prostate cancer deaths by about a fifth. However, due to the risk of over-diagnosis and overtreatment, routine PSA screening is not currently recommended.
The prostate cancer risk calculator has been updated to provide a more nuanced result, helping men understand their risk of low-grade and high-grade prostate cancer. The new calculator incorporates current risk factors and an advanced statistical model to distinguish between the prediction of low-grade and high-grade disease.
A new epigenetic test has been validated to accurately predict prostate cancer risk, eliminating the need for unnecessary repeat biopsies. The test demonstrated a negative predictive value of 90% in one trial and 88% in another, confirming its potential as a diagnostic aid.
Prostate cancer in younger men is more frequent and aggressive, with tumors growing quickly. Genetic mutations are a key factor in these cases, which may require increased surveillance or counseling.
Two studies suggest that primary androgen deprivation therapy (ADT) for low-risk prostate cancer is not associated with improved survival rates. Alternative treatments may be more effective for patients, but must consider the potential adverse effects and costs of ADT.
A new study found that physicians play a crucial role in determining whether older men with low-risk prostate cancer receive treatment or undergo active surveillance. Researchers identified significant variations in treatment and observation rates among urologists, with urologist characteristics accounting for more than double the rate...
A UCLA study found that depressed men with localized prostate cancer were more likely to be diagnosed with aggressive cancer, received less effective treatments, and had shorter survival times. The study identified demographic factors that contributed to the disparity in treatment and outcomes.
A study from Harvard School of Public Health found that vasectomy is associated with an increased risk of prostate cancer, including advanced and lethal forms. The association remained even among men who received regular PSA screening, suggesting a potential link between the procedure and aggressive prostate cancer.
A new study by the Endocrine Society found that BPA reprograms human fetal prostate tissue, increasing the risk of precancerous lesions. Exposure to low doses of BPA was shown to alter fetal prostate formation and increase stem cells, potentially leading to disease with aging.
Men with prostate cancer who played football for 12 weeks experienced significant gains in muscle mass and strength despite undergoing androgen deprivation therapy. The study also highlighted the positive social experiences and desire to remain active that came from playing football.
A survey of urologists and radiation oncologists found that most specialists view active surveillance as an effective treatment option but often fail to recommend it for their own patients. Instead, they tend to recommend treatments provided by their own specialty.
The American Cancer Society has released guidelines to support primary care of estimated 2.8 million men with a history of prostate cancer in the US. The guidelines outline posttreatment clinical follow-up care for long-term and late effects, including health promotion, surveillance for recurrence, and management of physical and psycho...
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A study published in Endocrine-Related Cancer has identified specific molecules in seminal fluid that can detect prostate cancer and predict its severity. The presence of these microRNAs, particularly miR-200b, shows promise as a prognostic tool for indicating treatment urgency and type.
The clinical validation study showed ProMark correctly identified low-risk disease with a sensitivity of 90% or better. The test provided additional independent prediction relative to standard risk-stratification systems, improving personalized treatment decisions for prostate cancer patients.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A new study found that prostate cancer patients who underwent external beam radiation therapy were 70% more likely to develop rectal cancer and 40% more likely for bladder cancer. Survivors should be aware of symptoms such as pelvic pain, difficulty urinating, or blood in stool to monitor for potential secondary cancers.
A behavior-altering enzyme commonly used in depression medications has been linked to prostate cancer growth. Suppressing this enzyme may reduce or eliminate prostate tumor growth and metastasis, offering a potential new treatment for men with metastatic prostate cancer.
Research suggests circumcision may reduce prostate cancer risk in certain populations, including Black men with a 60% lower risk. The study found no significant association between circumcision and prostate cancer risk for other ancestral groups.
A commercial epigenetic diagnostic test has been found to be accurate enough to exclude the need for repeat prostate biopsies in many men. The test analyzes DNA hypermethylation levels in specific genes and shows an 88% likelihood of no cancer when all three biomarkers are absent.
A recent study by Northwell Health demonstrates that magnetic resonance imaging (MRI) guided biopsies can detect prostate cancer more accurately, with a detection rate twice as high as previous data. The new targeted approach uses MRI and transrectal ultrasound fusion to identify clinically significant prostate cancer.
The Prolaris test accurately predicted 10-year death rates from prostate cancer and outperformed antiquated upgrading practice. In conservatively managed patients, the test differentiated high-risk disease from lower-risk disease.
A nationwide patient survey found that robot-assisted radical prostatectomy (RARP) is as safe as open surgery for Medicare patients over 65, but with higher costs. The study compared post-operative complications, blood transfusions, and hospital stays between RARP and open surgery.
A new UCLA study reveals that conventional biopsies may fail to detect aggressive cancers in men with low-risk prostate cancer, highlighting the need for a targeted biopsy approach. The findings suggest that the criteria for active surveillance should be re-evaluated to account for the risk inflation seen with targeted prostate biopsy.
Researchers have identified a new microRNA, hsa-miR-765, that suppresses expression of HMGA1 in prostate cancer cells, offering potential as a targeted therapy. The microRNA is activated by an FDA-approved anti-estrogen drug, fulvestrant.
Two new genes, FOXM1 and CENPF, linked to more aggressive prostate cancer have been discovered. A new approach in the treatment of these patients is being developed using computer algorithms and biomarkers.
A study by UCLA researchers found that treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies does not help them live longer. In fact, it can be detrimental and result in additional health issues such as impotence, urinary incontinence, and bowel problems.
Researchers discovered that FOXM1 and CENPF genes synergistically activate pathways associated with the most aggressive form of prostate cancer. The study identified these genes as a key driver pair in both mice and humans, and found that co-expression correlated with poor disease outcomes.
Men with low-risk prostate cancer who have low testosterone levels may be at increased risk of developing more aggressive disease. Low levels of free testosterone were significantly linked to an increased risk, suggesting a contradictory role for testosterone in prostate cancer progression.
A study found that vitamin D deficiency was associated with aggressive prostate cancer diagnosis and tumor progression in both European-American and African-American men. Lower levels of 25-hydroxyvitamin D (25-OH D) were linked to higher odds of having aggressive prostate cancer and faster disease progression.
A new study from Northwestern Medicine and the University of Illinois at Chicago finds that vitamin D deficiency is a predictor of aggressive forms of prostate cancer diagnosis in African-American and European-American men. Regular screenings for vitamin D deficiency could be crucial to prevent advanced tumor progression.
A novel electronic nose technique has been successfully used to discriminate between prostate cancer and benign prostatic hyperplasia in a proof-of-principle study. The eNose system demonstrated sensitivity and specificity comparable to traditional testing methods, such as prostate-specific antigen (PSA), with rapid and non-invasive re...
A new computational model simulates bone metastasis of prostate cancer and accurately predicts the impact of potential therapies on cancer cells and normal cells of the bone. The model was validated by comparing its predictions with tumor growth rates in mice, and identified critical players and events in the process of bone metastasis.
Research refines association between cardiovascular disease risk factors and prostate cancer, highlighting LDL cholesterol and triglycerides as key players. The study identifies 17 related gene loci that contribute to both high blood lipid levels and prostate cancer risk.
Researchers at Michigan Medicine have found that BET bromodomain protein 4 binds to the hormone androgen receptor, making it a potential target for prostate cancer treatment. The study suggests that a drug targeting this protein could work even when prostate cancer becomes resistant to current therapies.
A new study found that chronic inflammation in non-cancerous prostate tissue may increase a man's risk of developing high-grade prostate cancer by nearly twice. The study showed that men with signs of chronic inflammation had a higher risk of having an aggressive and rapidly growing prostate cancer.
A study found that chronic inflammation in benign prostate tissue was associated with high-grade prostate cancer. Men with at least one biopsy core showing inflammation had a 1.78 times higher odds of having prostate cancer and a 2.24 times higher odds of having aggressive disease.
A new method using existing ultrasound scanners allows doctors to accurately detect prostate cancer with much greater precision, reducing the need for painful biopsies. The technique saves money by eliminating costly biopsy analysis and can potentially eliminate biopsies altogether.
A clinical trial found that six months of hormone therapy added to radiotherapy significantly reduces the risk of prostate cancer relapse and progression. Men who received both treatments had a nearly 50% lower risk of biochemical progression compared to those treated with radiotherapy alone.
Researchers develop a technique to trick prostate cancer cells into using more glucose for imaging via PET scans, reducing the need for repeated biopsies. This method has potential therapeutic applications by cutting off cancer cells' energy supply from lipids.
Researchers found that circumcised men were 45% less at risk of developing prostate cancer than uncircumcised men. The protective effect was strongest among black men, who were 60% less likely to develop the disease if circumcised after age 35.
Researchers developed a genetic signature to identify men at high risk of prostate cancer recurrence after surgery or radiotherapy. The test uses DNA analysis from biopsy tissue and shows promise in predicting treatment failure with close to 80% accuracy.
A study found that permanent brachytherapy preserves erectile function in approximately 50% of prostate cancer patients, improving treatment outcomes. Researchers call for further training on discussing and assessing sexual side-effects of radiation treatment to ensure adequate patient information.
A recent study published in JAMA found that taking daily tadalafil did not prevent erectile dysfunction (ED) in men undergoing radiation therapy for prostate cancer. The study involved 242 men who received either tadalafil or a placebo, and showed no significant difference in ED prevention between the two groups.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
QUT Professor Colleen Nelson leads an international team of researchers in developing new drugs and treatments for aggressive prostate cancer. The team aims to understand the impact of current treatments on metabolic dysfunction and patient wellbeing, with the goal of improving treatment outcomes.
A comprehensive study of over 15,000 men with localized prostate cancer found that primary androgen deprivation therapy does not extend survival. The treatment is associated with serious adverse events and mitigates against its use as a primary treatment option.
The number of PSA screenings performed by doctors declined significantly after the 2012 USPSTF recommendations, with a greater impact seen among urologists.
Researchers found that MicroRNA-34 can suppress prostate cancer when paired with p53, but not individually. The study used mice models and found that combined silencing of miR-34 and p53 led to uncontrolled stem cell growth and high levels of cancer.
A new study by Yale University researchers found that a faster and less expensive form of radiotherapy for treating prostate cancer may come with a higher rate of urinary complications. Stereotactic body radiotherapy (SBRT) is a newer treatment option that can be completed in one to two weeks, compared to seven to nine weeks for intens...
Research from Umeå University and Memorial Sloan Kettering Cancer Center found that frequent PSA testing in areas with high incidence rates results in lower prostate cancer mortality. However, this is offset by increased risk of overtreatment, which can lead to side effects such as erectile dysfunction and urinary incontinence.
A new approach to prostate cancer screening is needed, focusing on high-risk men rather than the entire population. The risk-based approach uses a computer-generated calculator that assesses factors like PSA levels, family history, and ethnicity to identify those at greatest risk.
Scientists at the University of Surrey have developed a new test to detect prostate and bladder cancers, showing twice the effectiveness of the existing PSA blood test. The EN2 biomarker test is being commercialized by Randox Laboratories and could lead to faster detection and cost savings.
A new study finds that radical prostatectomy reduces mortality in men under 65, while still benefiting older men by reducing metastases and treatment needs. The research used data from the Scandinavian Prostate Cancer Group Study Number 4, which randomized 695 men to surgery or watchful waiting with no initial treatment.